靶向骨髓间充质基质细胞来源的IL-6以克服急性髓系白血病化疗耐药
研究利用Prrx1-Cre系统在骨髓间充质基质细胞(MSC)中选择性敲除Il6并建立AML小鼠模型,发现MSC是AML骨髓IL-6的主要来源。MSC中Il6缺失降低AML细胞氧化磷酸化(OXPHOS)活性、延缓疾病进展并增强对阿糖胞苷(Ara-C)的化疗敏感性,外源性重组IL-6可逆转该效应;OXPHOS抑制剂IACS-010759同样改善化疗敏感性。
要点
- 骨髓MSC是AML骨髓中IL-6的主要来源。
- MSC中Il6缺失降低AML细胞OXPHOS活性并增强Ara-C化疗敏感性。
- OXPHOS抑制剂IACS-010759改善AML小鼠化疗敏感性。
核心结论
- MSC来源的Il6在AML进展和化疗耐药中起关键作用,靶向MSC中的IL-6可能为AML提供有前景的治疗策略。
研究设计与样本
- 使用Prrx1-Cre系统在骨髓间充质基质细胞中选择性敲除Il6并建立AML小鼠模型。
- 试验注册于www.clinicaltrials.gov,注册号NCT06486350。
主要发现
- MSC是AML骨髓中IL-6的主要来源。
- MSC中Il6缺失降低AML细胞OXPHOS活性、延缓疾病进展并增强对Ara-C的化疗敏感性。
- OXPHOS抑制剂IACS-010759改善AML小鼠的化疗敏感性。
- 外源性重组IL-6逆转Il6缺失带来的化疗敏感性增益。
- MSC中Il6缺失抑制线粒体向AML细胞转移,削弱OXPHOS并增强Ara-C疗效。
临床怎么用
- 作者认为靶向MSC中的IL-6可能为AML提供有前景的治疗策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In acute myeloid leukemia (AML), elevated interleukin 6 (IL-6) levels in the bone marrow (BM) are linked to poor prognosis. However, the mechanisms driving this elevation and its role in chemoresistance remain unclear. Using the Prrx1-Cre system, we selectively deleted Il6 in BM mesenchymal stromal cells (MSCs) and established an AML mouse model. Our results show that MSCs are a major source of IL-6 in AML BM. Importantly, Il6 deletion in MSCs reduced oxidative phosphorylation (OXPHOS) activity in AML cells, slowed disease progression, and enhanced chemosensitivity to cytarabine (Ara-C). Similarly, the OXPHOS inhibitor IACS-010759 improved chemosensitivity in AML mice. Exogenous recombinant IL-6 reversed the chemosensitivity gains from Il6 deletion, confirming its role in chemoresistance. We further demonstrated that Il6 absence in MSCs inhibits mitochondria transfer to AML cells, dampening OXPHOS and enhancing Ara-C efficacy. In summary, our study underscores the critical role of Il6 from MSCs in AML progression and chemoresistance. Targeting IL-6 in MSCs may offer a promising therapeutic strategy for AML. This trial was registered at www.clinicaltrials.gov as #NCT06486350.
引用
- Hou D, Cai D, Dai W, et al. Targeting bone marrow mesenchymal stromal cell-derived IL-6 to overcome acute myeloid leukemia chemoresistance. Blood Adv. 2025. PMID: 40668612. doi:10.1182/bloodadvances.2024015496
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。